Table 2:

Number of participants included in the original study and the follow-up study

GroupOriginal studyFollow-up study
Enrolled (Oxford)*Completed (Oxford)*At baselineAt 1 moAt 2 moAt 3 mo
EnrolledIncluded in ITT analysis for persistenceReceived first doseIncluded in ITT analysis for immunogenicityReceived second doseIncluded in ITT analysis for immunogenicity
4CMenB246-1250 (46)45 (41)19171919NANA
rMenB246-12§48 (44)44 (40)29292928NANA
4CMenB-1224 (22)23 (21)888788
rMenB-12**25 (23)24 (23)141414131413
Control††NANA434042384136
  • 4CMenB = multicomponent serogroup B meningococcal vaccine, ITT = intention-to-treat, NA = not applicable, rMenB = recombinant protein serogroup B meningococcal vaccine.

  • * Because the follow-up study was a single-centre study, only participants recruited from Oxford (in parentheses) in the original study were invited to participate in the follow-up study.

  • Exclusions from the ITT analysis are due to lack of evaluable serum sample, except for 1 participant in the control group who withdrew consent.

  • Participants who received 4 doses of 4CMenB vaccine at 2, 4, 6 and 12 months.

  • § Participants who received 4 doses of rMenB vaccine at 2, 4, 6 and 12 months.

  • Participants who received 1 dose of 4CMenB at 12 months.

  • ** Participants who received 1 dose of rMenB vaccine at 12 months.

  • †† Participants with no previous exposure to 4CMenB or rMenB vaccines.